SIOP Asia in Mongolia Was a Great Success
15 Posts Not To Miss From ASCO Breakthrough 2026
Guatemala Officially Enacts New Regulation for Comprehensive Cancer Care
Liang Cheng: Transforming the Treatment Landscape of Urothelial Carcinoma
T-Bren Shows Early Activity Across HER2-Positive and HER2-Low Advanced Breast Cancer
Oncology Community Welcomes Two New FDA Approvals for Breast Cancer
Gold After Cancer: Summer Olympians Who Returned to Win Medals
Inside DeepHealth: How RadNet's AI Bet Is Reshaping the Business of Radiology
Enter RS and clinical context to view RS category and trial-aligned interpretation for early HR+/HER2- breast cancer.
This calculator is intended for ER/PR+ HER2- breast cancer only
TAILORx (Node-negative): Demonstrated that chemotherapy provides minimal to no benefit for most patients with RS 11-25. For patients ≤50 years, some benefit may be seen in RS 16-25.
RxPONDER (Node-positive, 1-3 nodes): Showed that postmenopausal patients with RS 0-25 did not benefit from chemotherapy. Premenopausal patients derived benefit regardless of RS.
RS Categories:
Low
0-10
Intermediate
11-25
High
26-100
